Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant

Cancer

Volumn 119, Issue 23, 2013, Pages 4188-4195

  Jones, Desiree ^a   Vichaya, Elisabeth G ^a   Wang, Xin Shelley ^a   Sailors, Mary H ^a   Cleeland, Charles S ^a   Wefel, Jeffrey S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

autologous transplant; cognitive impairment; induction chemotherapy; MDASI; multiple myeloma; neuropsychological testing; patient reported outcomes

Indexed keywords

ACUTE DISEASE; ADULT; ARTICLE; ATTENTION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EXECUTIVE FUNCTION; FEMALE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL DETERIORATION; MULTIPLE MYELOMA; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; TREATMENT OUTCOME;

AUTOLOGOUS TRANSPLANT; COGNITIVE IMPAIRMENT; INDUCTION CHEMOTHERAPY; MDASI; MULTIPLE MYELOMA; NEUROPSYCHOLOGICAL TESTING; PATIENT-REPORTED OUTCOMES;

ACUTE DISEASE; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEARNING; LONGITUDINAL STUDIES; MALE; MEMORY; MIDDLE AGED; MULTIPLE MYELOMA; TRANSPLANTATION, AUTOLOGOUS;

EID: 84888010789     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28323     Document Type: Article

References (38)

1. Brenner H, Gondos A, Pulte D,. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008; 111: 2521-2526.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111: 2516-2520.
3. Catley L, Anderson K,. Strategies to improve the outcome of stem cell transplantation in multiple myeloma. Hematol J. 2004; 5: 9-23.
4. Chapko MK, Syrjala KL, Schilter L, Cummings C, Sullivan KM,. Chemoradiotherapy toxicity during bone marrow transplantation: time course and variation in pain and nausea. Bone Marrow Transplant. 1989; 4: 181-186.
5. Ahles TA, Tope DM, Furstenberg C, Hann D, Mills L,. Psychologic and neuropsychologic impact of autologous bone marrow transplantation. J Clin Oncol. 1996; 14: 1457-1462.
6. Syrjala KL, Artherholt SB, Kurland BF, et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol. 2011; 29: 2397-2404.
7. Syrjala KL, Dikmen S, Langer SL, Roth-Roemer S, Abrams JR,. Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant. Blood. 2004; 104: 3386-3392.
8. Andrykowski MA, Schmitt FA, Gregg ME, Brady MJ, Lamb DG, Henslee-Downey PJ,. Neuropsychologic impairment in adult bone marrow transplant candidates. Cancer. 1992; 70: 2288-2297.
9. Harder H, Cornelissen JJ, Van Gool AR, Duivenvoorden HJ, Eijkenboom WM, van den Bent MJ,. Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation. Cancer. 2002; 95: 183-192.
10. Molassiotis A, Wilson B, Blair S, Howe T, Cavet J,. Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners. Psychooncology. 2011; 20: 88-97.
11. Potrata B, Cavet J, Blair S, Howe T, Molassiotis A,. 'Like a sieve': an exploratory study on cognitive impairments in patients with multiple myeloma. Eur J Cancer Care (Engl). 2010; 19: 721-728.
12. Friedman MA, Fernandez M, Wefel JS, Myszka KA, Champlin RE, Meyers CA,. Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. Arch Clin Neuropsychol. 2009; 24: 689-698.
13. Jacobs SR, Small BJ, Booth-Jones M, Jacobsen PB, Fields KK,. Changes in cognitive functioning in the year after hematopoietic stem cell transplantation. Cancer. 2007; 110: 1560-1567.
14. Beck AT, Brown G, Steer RA,. Beck Depression Inventory II Manual. San Antonio, TX: The Psychological Corp.; 1996.
15. Shah N, Jones D, Mendoza TR, et al. Validation of the M. D. Anderson Symptom Inventory Multiple Myeloma Module. Abstract 6551. In: Proceedings of the 48th Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; June 1-5, 2012; 277.
16. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000; 89: 1634-1646.
17. Benedict RHB, Schretlen D, Groninger L, Brandt J,. Hopkins verbal learning test revised: normative data and analysis of inter-form and test-restest reliability. Clin Neuropsychol. 1998; 12: 43-55.
18. Heaton RK, Miller SW, Taylor MJ, et al. Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery. Odessa, FL: Psychological Assessment Resources; 2004.
19. Ruff RM, Light RH, Parker SB, Levin HS,. Benton Controlled Oral Word Association Test: reliability and updated norms. Arch Clin Neuropsychol. 1996; 11: 329-338.
20. Tombaugh TN,. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004; 19: 203-214.
21. Wechsler D,. Wechsler Adult Intelligence Scale III. San Antonio, TX: The Psychological Corp.; 1997.
22. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA,. 'Chemobrain' in breast carcinoma?: a prologue. Cancer. 2004; 101: 466-475.
23. Chelune GJ, Naugle RI, Luders H, et al. Individual change after epilepsy surgery: practice effects and base-rate information. Neuropsychology. 1993; 7: 41-52.
24. Jacobson NS, Truax P,. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991; 59: 12-19.
25. Cleeland CS,. The M.D. Anderson Symptom Inventory User Guide. Houston, TX: MD Anderson Cancer Center; 2010.
26. Wefel JS, Vidrine DJ, Veramonti TL, et al. Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer. 2011; 117: 190-196.
27. Meyers CA, Byrne KS, Komaki R,. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer. 1995; 12: 231-235.
28. Meyers CA,. Neuropsychological aspects of cancer and cancer treatment. Phys Med Rehabil. 1994; 8: 229-241.
29. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA,. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010; 116: 3348-3356,.
30. Weis J, Poppelreuter M, Bartsch HH,. Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: 'subjective' complaints and 'objective' neuropsychological test results. Psychooncology. 2009; 18: 775-782.
31. Johnson I, Tabbane K, Dellagi L, Kebir O,. Self-perceived cognitive functioning does not correlate with objective measures of cognition in schizophrenia. Compr Psychiatry. 2011; 52: 688-692.
32. Ganz PA, Kwan L, Castellon SA, et al. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. J Natl Cancer Inst. 2013; 105: 791-801.
33. Wechsler D,. Wechsler Adult Intelligence Scale-Revised. San Antonio, TX: The Psychological Corp.; 1981.
34. Reitan RM,. Trail Making Test Manual for Administration and Scoring. Tucson, AZ: Reitan Neuropsychology Laboratory; 1992.
35. Levine AJ, Miller EN, Becker JT, Selnes OA, Cohen BA,. Normative data for determining significance of test-retest differences on eight common neuropsychological instruments. Clin Neuropsychol. 2004; 18: 373-384.
36. Brandt J,. The Hopkins Verbal Learning Test: development of a new memory test with 6 equivalent forms. Clin Neuropsychol. 1991; 5: 125-142.
37. Benton AL, Hamsher K,. Multilingual Aphasia Examination. Iowa City, IA: AJA Associates 1983.
38. Trites R,. Neuropsychological Test Manual. Ottawa, ON: Royal Ottawa Hospital; 1977.